Loading…
Nurix Therapeutics, Inc. is projected to rise to $22.29 by 2027, a +28% move from its current price of $17.47. NRIX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $17.06 | $17.48 | $17.91 | +0.05% |
| May 30 | $16.90 | $17.49 | $18.10 | +0.11% |
| May 31 | $16.78 | $17.50 | $18.25 | +0.16% |
| Jun 1 | $16.68 | $17.51 | $18.38 | +0.21% |
| Jun 2 | $16.59 | $17.52 | $18.50 | +0.26% |
| Jun 3 | $16.51 | $17.53 | $18.60 | +0.32% |
| Jun 4 | $16.44 | $17.53 | $18.70 | +0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.44 | $17.53 | $18.70 | +0.37% |
| Week 2 | $16.07 | $17.60 | $19.28 | +0.74% |
| Week 3 | $15.80 | $17.66 | $19.75 | +1.11% |
| Week 4 | $15.59 | $17.73 | $20.17 | +1.48% |
| Week 5 | $15.41 | $17.79 | $20.55 | +1.85% |
| Week 6 | $15.25 | $17.86 | $20.91 | +2.23% |
| Week 7 | $15.12 | $17.93 | $21.25 | +2.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. It develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A.
(Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc.
in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Nurix Therapeutics, Inc. trades under the NRIX ticker. It has a current price of $17.50 and a market capitalization of $1.81B, with a rank of 2067. The 2026 forecast for NRIX shows a min of $14.43, an avg of $17.50, and a max of $26.06, with a neutral sentiment and ROI 0.
The multi-year forecast projects bullish sentiment in later years, with the 2030 avg at $26.41 and ROI 50.9, the 2040 avg at $67.70 and ROI 286.8, and the 2050 avg at $128.79 and ROI 636. These figures imply meaningful upside beyond the near term.
A major floor 17.4% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.3% away) — a breakout level to watch.
A major ceiling 11.1% above — clearing it would confirm fresh momentum.
Key NRIX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NRIX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.26 | Buy | $17.15 | Buy |
| MA 10 | $16.51 | Buy | $16.82 | Buy |
| MA 20 | $16.53 | Buy | $16.61 | Buy |
| MA 50 | $16.14 | Buy | $16.39 | Buy |
| MA 100 | $16.53 | Buy | $16.09 | Buy |
| MA 200 | $14.54 | Buy | $15.44 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.38 | Neutral |
| Stoch RSI (14) | 95.69 | Sell |
| CCI (20) | 122.94 | Buy |
| Williams %R (14) | -2.62 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 5.75 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 97.38 | Sell |
| TRIX (15) | 0.07 | Buy |
| Awesome (5,34) | 0.69 | Buy |
| Ultimate (7,14,28) | 66.91 | Neutral |
| Momentum (10) | 1.51 | Buy |
| Aroon Osc (25) | 8.00 | Buy |
| Hull MA (9) | 17.94 | Sell |
| ADX (14) | 13.30 | Neutral |
| ATR (14) | 0.35 | Info |
The 30-day technical picture is bullish, with RSI14 at 60. The 50-day simple moving average is $16.05 and the 200-day simple moving average is $14.47. Near-term support is at $15.24 and resistance at $17.53. The 30-day price range spans from $14.76 to $20.75, indicating a constructive setup within a relatively tight band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.43 | $17.47 | $25.79 | 0% | Neutral | |
| $17.86 | $22.29 | $29.35 | +28% | Bullish | |
| $18.80 | $24.03 | $32.68 | +38% | Bullish | |
| $19.92 | $25.97 | $36.23 | +49% | Bullish | |
| $19.88 | $26.38 | $37.61 | +51% | Bullish | |
| $22.72 | $30.63 | $44.51 | +75% | Bullish | |
| $26.11 | $35.73 | $52.83 | +105% | Bullish | |
| $28.02 | $38.89 | $58.41 | +123% | Bullish | |
| $31.38 | $44.14 | $67.25 | +153% | Bullish | |
| $30.38 | $43.28 | $66.84 | +148% | Bullish | |
| $44.66 | $67.40 | $110.11 | +286% | Bullish | |
| $77.49 | $128.96 | $228.91 | +638% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $14.43 | $17.47 | $20.46 | +0.00% |
| June 2026 | $14.98 | $17.55 | $21.02 | +0.45% |
| July 2026 | $15.53 | $18.33 | $22.22 | +4.43% |
| August 2026 | $15.83 | $18.80 | $23.00 | +2.59% |
| September 2026 | $15.82 | $18.87 | $23.27 | +0.39% |
| October 2026 | $16.32 | $19.55 | $24.27 | +3.60% |
| November 2026 | $16.99 | $20.43 | $25.52 | +4.51% |
| December 2026 | $17.01 | $20.53 | $25.79 | +0.49% |
Click any year to see its month-by-month NRIX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NRIX could reach as high as $25.79, with a base case around $17.47 and support toward $14.43 — roughly 0% from $17.47. Price action looks broadly range-bound.
Expect NRIX to range from $17.86 to $29.35 through 2027. The $22.29 average target implies a +28% move from current prices. That is up +28% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The NRIX price prediction for 2028 points to an average of $24.03 (low $18.80, high $32.68) — a potential gain of +38% on today's $17.47. Momentum favours further upside here.
In 2029, NRIX is projected to trade between $19.92 and $36.23, averaging $25.97 — a potential gain of +49% from today's $17.47. That is up +8% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Nurix Therapeutics, Inc.'s 2030 outlook centres on $26.38, within a $19.88 to $37.61 range. That is up +2% on the projected 2029 average. That marks a +51% change versus current levels. Momentum favours further upside here.
By 2031, NRIX could reach as high as $44.51, with a base case around $30.63 and support toward $22.72 — roughly +75% from $17.47. Buyers look set to stay in control over this stretch.
Expect NRIX to range from $26.11 to $52.83 through 2032. The $35.73 average target implies a +105% move from current prices. That is up +17% on the projected 2031 average. Momentum favours further upside here.
The NRIX price prediction for 2033 points to an average of $38.89 (low $28.02, high $58.41) — a potential gain of +123% on today's $17.47. Buyers look set to stay in control over this stretch.
In 2034, NRIX is projected to trade between $31.38 and $67.25, averaging $44.14 — a potential gain of +153% from today's $17.47. That is up +13% on the projected 2033 average. Momentum favours further upside here.
Nurix Therapeutics, Inc.'s 2035 outlook centres on $43.28, within a $30.38 to $66.84 range. That is -2% versus the projected 2034 average. That marks a +148% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NRIX could reach as high as $110.11, with a base case around $67.40 and support toward $44.66 — roughly +286% from $17.47. Momentum favours further upside here.
Expect NRIX to range from $77.49 to $228.91 through 2050. The $128.96 average target implies a +638% move from current prices. That is up +91% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NRIX today (≈ 57.240985 NRIX) could be worth
$7,381.68
+$6,381.68 (+638%) by 2050 · US Dollar
Based on the average projected NRIX price of $128.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NRIXwould be worth at today's price.
$1,000 invested in NRIX on May 27, 2025 (≈ 102.354141 NRIX) would be worth
$1,788.13
+$788.13 (+78.8%) today · 1.79× · US Dollar
Based on a NRIX entry price of $9.77 vs. today's $17.47.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.42 | $1,063.95 | +6.4% |
| 1 month ago | $16.49 | $1,059.43 | +5.9% |
| 3 months ago | $16.11 | $1,084.42 | +8.4% |
| 6 months ago | $17.68 | $988.12 | -1.2% |
| 1 year ago | $9.77 | $1,788.13 | +78.8% |
| All time (5.0y) ago | $28.58 | $611.27 | -38.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NRIX forecast.
Our base-case forecast reaches $35.00 around 2032.
Implied market cap at $35.00: $3.62B
The multi-year forecast shows a bullish path with steadily higher average prices and rising upside potential. For 2030, the average price is forecast at $26.41 with an ROI of 50.9 and bullish sentiment. By 2040, the average is forecast at $67.70 with an ROI of 286.8 and bullish sentiment, followed by a 2050 forecast at $128.79 with an ROI of 636 and bullish sentiment.
The implied trajectory suggests continued upside beyond 2026, with substantial spread between min and max forecasts in later years. As with all forecasts, these estimates are not guarantees and depend on future market and clinical development outcomes.
Tap a question to reveal the answer.
2030 min $19.71, avg $26.41, max $38.09; ROI 50.9; sentiment BULLISH.
Forecasts show bullish sentiment in 2027 onward, with 2027 avg $22.48 (ROI 28.5), 2028 avg $24.12 (ROI 37.9), 2029 avg $25.94 (ROI 48.2), and 2030 avg $26.41 (ROI 50.9).
Yes. The forecast shows a 2040 max of $112.59 and a 2050 max of $233.50, indicating $100 is within the predicted range.
Current price is $17.50 and market cap is $1.81B.
The 30-day range is $14.76 to $20.75.
Nurix Therapeutics, Inc. Community Discussion
0Share your Nurix Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.